During ablation for atrial fibrillation, is simultaneous renal artery ablation appropriate?

Journal of Human Hypertension

Volumn 27, Issue 12, 2013, Pages 707-714

  Hogarth, A J ^a   Dobson, L E ^a   Tayebjee, M H ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Atrial fibrillation; Blood pressure; Renal artery ablation

Indexed keywords

AMIODARONE; AMLODIPINE; CANDESARTAN; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; PERINDOPRIL; SPIRONOLACTONE; VALSARTAN;

ABLATION THERAPY; ACCESS SITE PSEUDOANEURYSM; AUTONOMIC NERVOUS SYSTEM; CATHETER; CATHETER ABLATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE CONTROL; FALSE ANEURYSM; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RATE; HEART TAMPONADE; HEMATOMA; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MAGNETIC AND ELECTROMAGNETIC EQUIPMENT; META ANALYSIS (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PULMONARY VEIN OBSTRUCTION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL ARTERY ABLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; SINUS RHYTHM; SYMPATHETIC NERVE; SYMPATHETIC TONE; THROMBOEMBOLISM; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANIMALS; ATRIAL FIBRILLATION; CATHETER ABLATION; HUMANS; HYPERTENSION; RENAL ARTERY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84887623664     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.75     Document Type: Review

References (89)

1. Barylski M, Malyszko J, Rysz J, Mysliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011; 7: 1055-1066.
2. Banach M, Aronow WS. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens 2012; 26: 641-643.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
5. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003; 108: 711-716.
6. Aronow WS, Banach M. Atrial fibrillation: the new epidemic of the ageing world. J Atrial Fibrillation 2009; 1: 337-361.
7. Lip GY, Kakar P, Watson T. Atrial fibrillation-the growing epidemic. Heart 2007; 93: 542-543.
8. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
9. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-844.
10. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation- Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-1794.
11. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
12. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41: 1690-1696.
13. Berruezo A, Tamborero D, Mont L, Benito B, Tolosana JM, Sitges M et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 2007; 28: 836-841.
14. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension-its identification and epidemiology. Nat Rev Nephrol 2013; 9: 51-58.
15. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
16. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K et al. Catheterbased renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
17. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-1170.
18. Boos CJ, Lip GY. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials. J Hum Hypertens 2005; 19: 855-859.
19. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996; 7: 999-1007.
20. Laszlo R, Bentz K, Konior A, Eick C, Schreiner B, Kettering K et al. Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 347-356.
21. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007; 120: 85-91.
22. Tayebjee MH, Creta A, Moder S, Hunter RJ, Earley MJ, Dhinoja MB et al. Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation. Europace 2010; 12: 1537-1542.
23. Madrid AH, Marin IM, Cervantes CE, Morell EB, Estevez JE, Moreno G et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5: 114-120.
24. Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A et al. Effect of combined spironolactone-beta-blocker-enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 2010; 106: 1609-1614.
25. Tardif J, Talajic M. Perindopril and prevention of atrial fibrillation. Eur Heart J Suppl 2007; 9: E25-E29.
26. Vaziri SM, Larson MG, Lauer MS, Benjamin EJ, Levy D. Influence of blood pressure on left atrial size. The Framingham Heart Study. Hypertension 1995; 25: 1155-1160.
27. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J 2000; 139: 814-819.
28. Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens 2012; 30: 239-252.
29. Piotrowski G, Banach M, Gerdts E, Mikhailidis DP, Hannam S, Gawor R et al. Left atrial size in hypertension and stroke. J Hypertens 2011; 29: 1988-1993.
30. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008; 51: 1-11.
31. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002; 90: 1284-1289.
32. Shi Y, Ducharme A, Li D, Gaspo R, Nattel S, Tardif JC. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001; 52: 217-225.
33. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
34. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
35. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-e198.
36. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
37. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA et al. 2012 HRS/ EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012; 9: 632-696 e621.
38. Kabra R, Singh J. Recent trends in imaging for atrial fibrillation ablation. Indian Pacing Electrophysiol J 2010; 10: 215-227.
39. Ouyang F, Ernst S, Chun J, Bansch D, Li Y, Schaumann A et al. Electrophysiological findings during ablation of persistent atrial fibrillation with electroanatomic mapping and double Lasso catheter technique. Circulation 2005; 112: 3038-3048.
40. Gewirtz JR, Bisognano JD. Catheter-based renal sympathetic denervation: a targeted approach to resistant hypertension. Cardiol J 2011; 18: 97-102.
41. Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat 2012; 25: 628-633.
42. Hogh Petersen H, Chen X, Pietersen A, Svendsen JH, Haunso S. Lesion dimensions during temperature-controlled radiofrequency catheter ablation of left ventricular porcine myocardium: impact of ablation site, electrode size, and convective cooling. Circulation 1999; 99: 319-325.
43. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54: 1195-1201.
44. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
45. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841.
46. Esler MDKH, Schlaich MP. Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18 month follow-up of the Symplicity HTN-2 trial. In: European Society of Cardiology 2012 Congress. Munich, Germany 2012.
47. Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F et al. Catheterbased renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
48. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909.
49. Taborsky MLM, Vaclavik J, Richter D. The effect of renal denervation in patients with advanced heart failure: OLOMOUCI 1 study. In: The European Society of Cardiology 2012 Congress. Munich, Germany 2012.
50. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 2011; 58: 1176-1182.
51. Verdino RJ. Catheter ablation for the treatment of atrial fibrillation: have we been targeting the wrong organ? J Am Coll Cardiol 2012; 60: 1171-1172.
52. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR et al. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension 2013; 61: 225-231.
53. Zhao Q, Yu S, Zou M, Dai Z, Wang X, Xiao J et al. Effect of renal sympathetic denervation on the inducibility of atrial fibrillation during rapid atrial pacing. J Interv Card Electrophysiol 2012; 35: 119-125.
54. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504.
55. Julius S. Abnormalities of autonomic nervous control in human hypertension. Cardiovasc Drugs Ther 1994; 8(Suppl 1): 11-20.
56. Folkow B. Sympathetic nervous control of blood pressure. Role in primary hypertension. Am J Hypertens 1989; 2: 103S-111S.
57. Carretero OA, Scicli AG. Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension. Hypertension 1991; 18: I58-I69.
58. Taddei S, Salvetti A. Pathogenetic factors in hypertension. Endothelial factors. Clin Exp Hypertens 1996; 18: 323-335.
59. Lee WK, Padmanabhan S, Dominiczak AF. Genetics of hypertension: from experimental models to clinical applications. J Hum Hypertens 2000; 14: 631-647.
60. O'Shaughnessy KM. The genetics of essential hypertension. Br J Clin Pharmacol 2001; 51: 5-11.
61. Ruppert V, Maisch B. Genetics of human hypertension. Herz 2003; 28: 655-662.
62. Reaven G. Insulin resistance, hypertension, and coronary heart disease. J Clin Hypertens (Greenwich) 2003; 5: 269-274.
63. Smith PA, Meaney JF, Graham LN, Stoker JB, Mackintosh AF, Mary DA et al. Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. J Am Coll Cardiol 2004; 43: 1453-1458.
64. Scott EM, Greenwood JP, Vacca G, Stoker JB, Gilbey SG, Mary DA. Carbohydrate ingestion, with transient endogenous insulinaemia, produces both sympathetic activation and vasodilatation in normal humans. Clin Sci (Lond) 2002; 102: 523-529.
65. Huggett RJ, Scott EM, Gilbey SG, Bannister J, Mackintosh AF, Mary DA. Disparity of autonomic control in type 2 diabetes mellitus. Diabetologia 2005; 48: 172-179.
66. Dickinson CJ. Cerebral oxidative metabolism in hypertension. Clin Sci (Lond) 1996; 91: 539-550.
67. Wallin BG, Kunimoto MM, Sellgren J. Possible genetic influence on the strength of human muscle nerve sympathetic activity at rest. Hypertension 1993; 22: 282-284.
68. Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364: 928-938.
69. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-1617.
70. Parkash R. Atrial substrate modification with aggressive blood pressure lowering to prevent AF (SMAC AF). Nova Scotia: Capital District Health Authority 2009.
71. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27: 512-518.
72. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55: 2299-2307.
73. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013; 61: 457-464.
74. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59: 1938-1945.
75. Lewis TDAN, Bulger HA. Observations upon flutter and fibrillation. VI. Refractory period and rate of propagation in the auricle: their relation to block in the auricular walls and to flutter etc. Heart 1921; 8: 83-134.
76. Hoff HE, Geddes LA. Cholinergic factor in auricular fibrillation. J Appl Physiol 1955; 8: 177-192.
77. Ardell JL. Neurocardiology. In: Armour JA, Ardell JL (eds). Structure and Function of Mammalian Intrinsic Cardiac Neurones. Oxford University Press: New York, 1994, pp 95-114.
78. Katritsis DG, Giazitzoglou E, Zografos T, Pokushalov E, Po SS, Camm AJ. Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. Heart Rhythm 2011; 8: 672-678.
79. Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 2012; 5: 758-765.
80. Ahmed H, Miller MA, Dukkipati SR, Cammack S, Koruth JS, Gangireddy S et al. Adjunctive renal sympathetic denervation to modify hypertension as upstream therapy in the treatment of atrial fibrillation (H-FIB) study: clinical background and study design. J Cardiovasc Electrophysiol 2013; 24: 503-509.
81. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
82. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
83. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
84. Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007; 154: 448-453.
85. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403-411.
86. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-336.
87. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.
88. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13: 473-479.
89. Richter B, Derntl M, Marx M, Lercher P, Gossinger HD. Therapy with angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153: 113-119.